Losartan in Treating Pulmonary Fibrosis Caused by Radiation Therapy in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer - Full Text View

Sponsor:	University of South Florida
Collaborator:	National Cancer Institute (NCI)
Information provided by:	National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:	NCT00880386

Purpose

RATIONALE: Losartan potassium may be effective in treating pulmonary fibrosis caused by radiation therapy in patients with non-small cell lung cancer.

PURPOSE: This clinical trial is studying losartan to see how well it works in treating pulmonary fibrosis caused by radiation therapy in patients with stage I, stage II, or stage III non-small cell lung cancer.

Condition	Intervention
Dyspnea Lung Cancer Pulmonary Complications Radiation Fibrosis	Drug: losartan potassium Other: questionnaire administration Procedure: breath test

Study Type:	Interventional
Study Design:	Primary Purpose: Supportive Care
Official Title:	A Pilot Project to Determine the Effect of Losartan (Cozaar) on Radiation-Induced Pulmonary Fibrosis in Patients With Non-Small Cell Lung Cancer

Resource links provided by NLM:

MedlinePlus related topics: Breathing Problems Cancer Lung Cancer Potassium Pulmonary Fibrosis

Drug Information available for: Losartan Losartan potassium

U.S. FDA Resources

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:

Change in carbon monoxide diffusing capacity (DLCO) at 6 months [ Designated as safety issue: No ]

Secondary Outcome Measures:

Feasibility of losartan potassium as treatment for radiation-induced pulmonary fibrosis [ Designated as safety issue: No ]
Pulmonary function measurements of FEV1 and FVC and dyspnea score at 6 months [ Designated as safety issue: No ]

Estimated Enrollment:	35
Study Start Date:	May 2009
Estimated Primary Completion Date:	November 2010 (Final data collection date for primary outcome measure)

Detailed Description:

OBJECTIVES:

Primary

To evaluate the effects of losartan potassium on the disease progression in patients with stage I-III non-small cell lung cancer and radiation-induced pulmonary fibrosis.
To determine the feasibility of losartan potassium as a possible treatment for radiation-induced pulmonary fibrosis.

Secondary

The evaluate the effects of losartan potassium on the degree of dyspnea, and lung function (FEV_1 and FVC) in these patients.

OUTLINE: This is a multicenter study.

Patients receive oral losartan potassium once daily for 6 months in the absence of disease progression or unacceptable toxicity.

Patients undergo assessment of pulmonary function (e.g., gas movement, lung capacity, and diffusion of gases) by spirometry and dyspnea by the Visual Analog Scale (VAS) at baseline and at weeks 12 and 24.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

DISEASE CHARACTERISTICS:

Diagnosis of non-small cell lung cancer
- Stage I, II, IIIA, or IIIB disease
Diagnosis of radiation therapy-induced pulmonary fibrosis within 2 years of last radiation treatment
- Grade I-III disease as defined by NCI CTCAE v3.0
- Diagnosis and grading based on radiographic changes of ≥ grade 1, defined as minimal radiographic findings (or patchy or bibasilar changes) with estimated radiographic proportions of total lung volume < 25% (if fibrotic)

PATIENT CHARACTERISTICS:

Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
Not currently smoking or smoked within the past 6 months
No baseline systolic blood pressure < 100 mm Hg
No bilateral renal artery stenosis, hereditary or idiopathic angioedema, or uncontrolled hypotension
No history of kidney failure or liver disease
Able to attend clinic visits
No allergy or allergic reaction to losartan potassium or any other angiotensin II receptor blocker

PRIOR CONCURRENT THERAPY:

See Disease Characteristics
More than 6 months since prior and no concurrent use of another angiotensin II receptor blocker (i.e., losartan potassium, valsartan, irbesartan, candesartan, cilexetil, eprosartan mesylate, or telmisartan)
No history of lung transplant
No prior pneumonectomy
No concurrent lithium

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00880386

Sponsors and Collaborators

University of South Florida

National Cancer Institute (NCI)

Investigators

Principal Investigator:

Marisa Couluris, DO

University of South Florida

More Information

Additional Information:

Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Viki Huegel, SunCoast CCOP Research Base at the University of South Florida
ClinicalTrials.gov Identifier:	NCT00880386 History of Changes
Other Study ID Numbers:	CDR0000637808, SCUSF-PILOT-0208, MCC-PILOT-0208
Study First Received:	April 10, 2009
Last Updated:	September 18, 2010
Health Authority:	Unspecified

Keywords provided by National Cancer Institute (NCI):

dyspnea
stage I non-small cell lung cancer
stage II non-small cell lung cancer
stage IIIA non-small cell lung cancer

stage IIIB non-small cell lung cancer
pulmonary complications
radiation fibrosis

Additional relevant MeSH terms:

Carcinoma, Non-Small-Cell Lung
Dyspnea
Fibrosis
Lung Neoplasms
Pulmonary Fibrosis
Radiation Pneumonitis
Carcinoma, Bronchogenic
Bronchial Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Respiration Disorders

Signs and Symptoms, Respiratory
Signs and Symptoms
Pathologic Processes
Lung Diseases, Interstitial
Lung Injury
Radiation Injuries
Wounds and Injuries
Losartan
Anti-Arrhythmia Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists

ClinicalTrials.gov processed this record on February 09, 2012